- Home
- STEL vs DAWN Comparison
STEL vs DAWN Comparison
Compare STEL & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEL
- DAWN
- Stock Information
- Founded
- STEL 2007
- DAWN 2018
- Country
- STEL United States
- DAWN United States
- Employees
- STEL N/A
- DAWN N/A
- Industry
- STEL Major Banks
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- STEL Finance
- DAWN Health Care
- Exchange
- STEL Nasdaq
- DAWN Nasdaq
- Market Cap
- STEL 1.4B
- DAWN 1.6B
- IPO Year
- STEL N/A
- DAWN 2021
- Fundamental
- Price
- STEL $29.96
- DAWN $13.31
- Analyst Decision
- STEL Hold
- DAWN Strong Buy
- Analyst Count
- STEL 3
- DAWN 7
- Target Price
- STEL $28.33
- DAWN $36.17
- AVG Volume (30 Days)
- STEL 191.3K
- DAWN 1.3M
- Earning Date
- STEL 10-25-2024
- DAWN 10-30-2024
- Dividend Yield
- STEL 1.74%
- DAWN N/A
- EPS Growth
- STEL 10.73
- DAWN N/A
- EPS
- STEL 2.19
- DAWN N/A
- Revenue
- STEL $438,640,000.00
- DAWN $101,953,000.00
- Revenue This Year
- STEL N/A
- DAWN N/A
- Revenue Next Year
- STEL $1.04
- DAWN $44.21
- P/E Ratio
- STEL $13.66
- DAWN N/A
- Revenue Growth
- STEL 3.93
- DAWN N/A
- 52 Week Low
- STEL $21.27
- DAWN $11.30
- 52 Week High
- STEL $30.92
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- STEL 64.50
- DAWN 35.44
- Support Level
- STEL $26.28
- DAWN $14.30
- Resistance Level
- STEL $30.61
- DAWN $15.92
- Average True Range (ATR)
- STEL 0.87
- DAWN 0.90
- MACD
- STEL 0.18
- DAWN -0.17
- Stochastic Oscillator
- STEL 79.31
- DAWN 0.29
About STEL Stellar Bancorp Inc.
Stellar Bancorp Inc is a U.S. based bank holding company. It mainly focuses on providing commercial banking solutions to local small and mid-sized businesses and professionals. The services provided by the company include business and personal deposits account, personal and business lending, mobile and online banking, merchant banking, and others. The company more than 50 full service banking centers.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.